Approvals for generic versions of the high-strength Ebixa 20mg (memantine hydrochloride), a treatment for severe Alzheimer's, that had been slowing down lately, have begun to gain momentum again.

On March 5, the Ministry of Food and Drug Safety approved Dongkook Pharmaceuticals 'Memantine Tab 20mg.'

Eighteen years after the 10mg formulation of the original memantine drug Ebixa (company: Lundbeck Korea) was approved in September 2003, the 20mg formulation that offers improved patient convenience had been released in November 2021.

Unlike how patients had to take the 10mg formulation twice daily, the higher-strength 20mg tablet formulation can be taken only once a day, significa